RNA logo

Avidity Biosciences (RNA) Cash from operations

annual CFO:

-$300.87M-$181.81M(-152.70%)
December 31, 2024

Summary

  • As of today (May 29, 2025), RNA annual cash flow from operations is -$300.87 million, with the most recent change of -$181.81 million (-152.70%) on December 31, 2024.
  • During the last 3 years, RNA annual CFO has fallen by -$206.06 million (-217.33%).
  • RNA annual CFO is now -12183.13% below its all-time high of $2.49 million, reached on December 31, 2019.

Performance

RNA Cash from operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherRNAcash flow metrics

quarterly CFO:

-$124.83M-$24.96M(-24.99%)
March 31, 2025

Summary

  • As of today (May 29, 2025), RNA quarterly cash flow from operations is -$124.83 million, with the most recent change of -$24.96 million (-24.99%) on March 31, 2025.
  • Over the past year, RNA quarterly CFO has dropped by -$54.45 million (-77.36%).
  • RNA quarterly CFO is now -856.49% below its all-time high of $16.50 million, reached on December 31, 2023.

Performance

RNA quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherRNAcash flow metrics

TTM CFO:

-$355.32M-$54.45M(-18.10%)
March 31, 2025

Summary

  • As of today (May 29, 2025), RNA TTM cash flow from operations is -$355.32 million, with the most recent change of -$54.45 million (-18.10%) on March 31, 2025.
  • Over the past year, RNA TTM CFO has dropped by -$214.84 million (-152.94%).
  • RNA TTM CFO is now -2752.82% below its all-time high of $13.39 million, reached on June 30, 2019.

Performance

RNA TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherRNAcash flow metrics

Cash from operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

RNA Cash from operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-152.7%-77.4%-152.9%
3 y3 years-217.3%-322.1%-239.3%
5 y5 years-10000.0%-1648.3%-10000.0%

RNA Cash from operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-217.3%at low-856.5%at low-239.3%at low
5 y5-year<-9999.0%at low-856.5%at low<-9999.0%at low
alltimeall time<-9999.0%at low-856.5%at low-2752.8%at low

RNA Cash from operations History

DateAnnualQuarterlyTTM
Mar 2025
-
-$124.83M(+25.0%)
-$355.32M(+18.1%)
Dec 2024
-$300.87M(+152.7%)
-$99.87M(+52.2%)
-$300.87M(+63.1%)
Sep 2024
-
-$65.61M(+0.9%)
-$184.50M(+18.5%)
Jun 2024
-
-$65.00M(-7.6%)
-$155.67M(+10.8%)
Mar 2024
-
-$70.38M(-526.5%)
-$140.48M(+18.0%)
Dec 2023
-$119.06M(-12.6%)
$16.50M(-144.9%)
-$119.06M(-31.9%)
Sep 2023
-
-$36.79M(-26.1%)
-$174.75M(+2.8%)
Jun 2023
-
-$49.81M(+1.7%)
-$169.92M(+9.2%)
Mar 2023
-
-$48.97M(+25.0%)
-$155.66M(+14.2%)
Dec 2022
-$136.27M(+43.7%)
-$39.19M(+22.6%)
-$136.27M(+10.5%)
Sep 2022
-
-$31.96M(-10.1%)
-$123.29M(+10.0%)
Jun 2022
-
-$35.55M(+20.2%)
-$112.12M(+7.1%)
Mar 2022
-
-$29.57M(+12.8%)
-$104.71M(+10.4%)
DateAnnualQuarterlyTTM
Dec 2021
-$94.81M(+155.4%)
-$26.21M(+26.1%)
-$94.81M(+16.1%)
Sep 2021
-
-$20.78M(-26.1%)
-$81.67M(+16.7%)
Jun 2021
-
-$28.14M(+43.0%)
-$70.00M(+41.0%)
Mar 2021
-
-$19.68M(+50.5%)
-$49.66M(+33.8%)
Dec 2020
-$37.12M(-1590.6%)
-$13.07M(+43.5%)
-$37.12M(+27.7%)
Sep 2020
-
-$9.11M(+17.0%)
-$29.06M(+12.5%)
Jun 2020
-
-$7.79M(+9.1%)
-$25.84M(+907.6%)
Mar 2020
-
-$7.14M(+42.3%)
-$2.56M(-203.0%)
Dec 2019
$2.49M(-125.8%)
-$5.02M(-14.7%)
$2.49M(-66.8%)
Sep 2019
-
-$5.88M(-138.0%)
$7.51M(-43.9%)
Jun 2019
-
$15.48M(-842.1%)
$13.39M(-742.1%)
Mar 2019
-
-$2.09M
-$2.09M
Dec 2018
-$9.65M
-
-

FAQ

  • What is Avidity Biosciences annual cash flow from operations?
  • What is the all time high annual CFO for Avidity Biosciences?
  • What is Avidity Biosciences annual CFO year-on-year change?
  • What is Avidity Biosciences quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Avidity Biosciences?
  • What is Avidity Biosciences quarterly CFO year-on-year change?
  • What is Avidity Biosciences TTM cash flow from operations?
  • What is the all time high TTM CFO for Avidity Biosciences?
  • What is Avidity Biosciences TTM CFO year-on-year change?

What is Avidity Biosciences annual cash flow from operations?

The current annual CFO of RNA is -$300.87M

What is the all time high annual CFO for Avidity Biosciences?

Avidity Biosciences all-time high annual cash flow from operations is $2.49M

What is Avidity Biosciences annual CFO year-on-year change?

Over the past year, RNA annual cash flow from operations has changed by -$181.81M (-152.70%)

What is Avidity Biosciences quarterly cash flow from operations?

The current quarterly CFO of RNA is -$124.83M

What is the all time high quarterly CFO for Avidity Biosciences?

Avidity Biosciences all-time high quarterly cash flow from operations is $16.50M

What is Avidity Biosciences quarterly CFO year-on-year change?

Over the past year, RNA quarterly cash flow from operations has changed by -$54.45M (-77.36%)

What is Avidity Biosciences TTM cash flow from operations?

The current TTM CFO of RNA is -$355.32M

What is the all time high TTM CFO for Avidity Biosciences?

Avidity Biosciences all-time high TTM cash flow from operations is $13.39M

What is Avidity Biosciences TTM CFO year-on-year change?

Over the past year, RNA TTM cash flow from operations has changed by -$214.84M (-152.94%)
On this page